Recognizing Symptoms and Warning Signs
At a Glance
MPAN usually causes gradual problems with walking, stiffness, speech, vision, thinking, and mood. Sudden swallowing or weakness changes need prompt evaluation, while breathing difficulty, prolonged seizures, severe psychiatric crisis, or stroke-like symptoms require emergency help.
While every person’s journey with MPAN is different, the condition follows a general pattern of progressive changes in movement, vision, and thinking. Because MPAN typically moves slowly, it is important to distinguish between the expected progression of the disease and “red flag” symptoms that require immediate medical attention [1].
Early Motor Symptoms
Movement challenges are often the first sign of MPAN. In a large retrospective study of 85 patients tracking symptoms over time, nearly everyone (99%) experienced gait disturbances, or trouble walking, as a symptom [1].
- Pyramidal Signs: Affecting 95% of patients in the cohort study, these are signs of damage to the brain’s motor pathways. They include spasticity (muscle stiffness), weakness, and exaggerated reflexes [1][2].
- Dysarthria: This is an impairment of motor control of speech, which can include slurring or slowing. While it eventually affects about 90% of patients in the cohort study, it often appears later in the disease course than walking difficulties [1].
- Muscle Atrophy: Some patients develop motor axonal neuropathy, where the nerves connecting the spine to the muscles are damaged, leading to visible muscle thinning or “wasting” [3][4].
Visual Manifestations
Vision loss is a hallmark of MPAN, affecting roughly 82% of patients in the cohort study [1]. This is usually caused by optic atrophy, a condition where the optic nerve—the cable connecting the eye to the brain—becomes thin and pale [5].
Unlike some other eye conditions, this typically does not involve the retina itself. Doctors may use Optical Coherence Tomography (OCT) to measure this thinning or Visual Evoked Potentials (VEP) to see how quickly signals travel from the eyes to the brain [5]. You may notice your child or yourself having more difficulty seeing in low light or failing to notice things in the periphery.
Cognitive and Psychiatric Symptoms
As MPAN progresses, it can affect the mind as well as the body. This is especially common in individuals whose symptoms began in adulthood [6].
- Cognitive Decline: This may start as subtle memory loss or difficulty with complex tasks, sometimes progressing to dementia [3][7].
- Psychiatric Changes: Some people experience significant mood or behavioral changes, including anxiety, depression, irritability, or social withdrawal [8][9]. In rare cases, these can be the very first symptoms noticed [1].
Distinguishing Routine Progression from Emergencies
Understanding what is “normal” for MPAN can help reduce anxiety and ensure you get help when it is truly needed.
Routine Progression (Monitor and Discuss at Next Visit)
These symptoms are expected to worsen gradually over years:
- Slowly Increasing Stiffness: A gradual increase in leg stiffness or a slow transition to using a walker or wheelchair [1].
- Gradual Speech Changes: Speech becoming slightly more difficult to understand over several months [1].
- Mild Balance Issues: Occasional stumbles that do not result in serious injury.
Call the Clinic Promptly
These represent acute complications that need urgent evaluation from your care team:
- Acute Dysphagia: A sudden inability to swallow, frequent choking, or a “wet” sounding voice during or after meals. This can lead to aspiration pneumonia (food or liquid entering the lungs) [10][11].
- Sudden Weakness or Falls: A rapid change in the ability to walk or stand over days rather than months.
Red Flags (Call Emergency Services)
These represent situations that need immediate emergency attention:
- Psychiatric Crisis: Sudden, severe agitation, hallucinations, or immediate thoughts of self-harm [8].
- Seizures: While not universal, epileptic seizures can occur in NBIA disorders. Any new loss of consciousness or rhythmic shaking that fails to stop after a few minutes or fails to recover consciousness is an emergency [12].
- Breathing Difficulty: New shortness of breath, inability to clear the airway, or a very weak cough [11].
- Stroke-like Symptoms: Sudden focal weakness or inability to speak.
Variability in Movement Disorders
Beyond stiffness, many patients develop other movement challenges:
- Dystonia: Involuntary muscle contractions that cause repetitive movements or twisting postures (e.g., a foot turning inward) [13].
- Parkinsonism: Symptoms similar to Parkinson’s disease, such as tremors, slowed movement (bradykinesia), and a stooped posture [2][3].
The prominence of these symptoms varies widely. Some patients may have severe dystonia while others experience mostly parkinsonism or spasticity [2]. Progress is being tracked through registries like TIRCON to better understand why these differences occur [NCT05522374].
Common questions in this guide
What symptoms usually appear first in MPAN?
What vision changes can MPAN cause?
When should swallowing problems in MPAN be reported?
Which MPAN warning signs require emergency help?
Can MPAN cause Parkinson-like or twisting movements?
How can families monitor thinking and mood changes in MPAN?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Has a formal swallow study (like a videofluoroscopy) been done to assess for silent aspiration?
- 2.Should we perform an Optical Coherence Tomography (OCT) to measure my/my child's retinal nerve fiber layer thickness?
- 3.Given the risk of parkinsonism and dystonia, are there specific medications that can help with muscle stiffness or tremors?
- 4.How often should we have a neuropsychiatric evaluation to monitor for cognitive or mood changes?
- 5.Are there signs of motor axonal neuropathy that might be contributing to muscle weakness or atrophy?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration.
Iankova V, Sparber P, Rohani M, et al.
Brain : a journal of neurology 2024; (147(4)):1389-1398 doi:10.1093/brain/awad357.
PMID: 37831662 - 2
Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12.
Skowronska M, Kmiec T, Jurkiewicz E, et al.
Parkinsonism & related disorders 2017; (39()):71-76 doi:10.1016/j.parkreldis.2017.03.013.
PMID: 28347614 - 3
The p.Thr11Met mutation in c19orf12 is frequent among adult Turkish patients with MPAN.
Olgiati S, Doğu O, Tufekcioglu Z, et al.
Parkinsonism & related disorders 2017; (39()):64-70 doi:10.1016/j.parkreldis.2017.03.012.
PMID: 28347615 - 4
The Downregulation of c19orf12 Negatively Affects Neuronal and Musculature Development in Zebrafish Embryos.
Mignani L, Zizioli D, Borsani G, et al.
Frontiers in cell and developmental biology 2020; (8()):596069 doi:10.3389/fcell.2020.596069.
PMID: 33425903 - 5
Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN).
Langwinska-Wosko E, Skowronska M, Kmiec T, Czlonkowska A
Journal of the neurological sciences 2016; (370()):237-240 doi:10.1016/j.jns.2016.09.046.
PMID: 27772766 - 6
C19orf12 gene variants causing mitochondrial membrane protein-associated neurodegeneration (MPAN).
Kumari R, Holla VV, Sriram N, et al.
European journal of human genetics : EJHG 2025; (33(7)):878-886 doi:10.1038/s41431-024-01778-6.
PMID: 39755877 - 7
Mitochondrial Membrane Protein-Associated Neurodegeneration: A Case Series of Six Children.
Incecik F, Herguner OM, Bisgin A
Annals of Indian Academy of Neurology 2020; (23(6)):802-804 doi:10.4103/aian.AIAN_268_19.
PMID: 33688131 - 8
Case Report: Identification of a De novo C19orf12 Variant in a Patient With Mitochondrial Membrane Protein-Associated Neurodegeneration.
Yang Y, Zhang S, Yang W, et al.
Frontiers in genetics 2022; (13()):852374 doi:10.3389/fgene.2022.852374.
PMID: 35432442 - 9
Clinical and imaging characteristics of late onset mitochondrial membrane protein-associated neurodegeneration (MPAN).
Gore E, Appleby BS, Cohen ML, et al.
Neurocase 2016; (22(5)):476-483 doi:10.1080/13554794.2016.1247458.
PMID: 27801611 - 10
Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
Patino J, Clearman AH, Miller L, Koenig MK
Clinical case reports 2024; (12(7)):e9116 doi:10.1002/ccr3.9116.
PMID: 38919884 - 11
Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration.
Klopstock T, Videnovic A, Bischoff AT, et al.
Movement disorders : official journal of the Movement Disorder Society 2021; (36(6)):1342-1352 doi:10.1002/mds.28392.
PMID: 33200489 - 12
NBIA Syndromes: A Step Forward from the Previous Knowledge.
Svetel M, Dragašević N, Petrović I, et al.
Neurology India 2021; (69(5)):1380-1388 doi:10.4103/0028-3886.329603.
PMID: 34747818 - 13
Mitochondrial membrane protein-associated neurodegeneration: a case report and literature review.
Dušek P, Školoudík D, Roth J, Dušek P
Neurocase 2018; (24(3)):161-165 doi:10.1080/13554794.2018.1506038.
PMID: 30088953
This page explains MPAN symptoms and warning signs for informational purposes only and does not constitute medical advice. Contact your care team about changes, and call emergency services for severe breathing problems, seizures, stroke-like symptoms, or immediate self-harm risk.
Get notified when new evidence is published on Mitochondrial membrane protein-associated neurodegeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.